LCLykourgos Chiniadis

Lykourgos Chiniadis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lykourgos Chiniadis has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors

    by Apostolia Gkoutzivelaki, Sotiria-Iro Triantopoulou, Lykourgos Chiniadis, Alexandros Komiotis, Charalampos Triantis, Dimitri Komiotis, Athanasios Papakyriakou, Harris Pratsinis, Stella Manta

    The epidermal growth factor receptor (EGFR) is a highly attractive and promising target for novel anticancer agents, particularly for non-small-cell lung cancer (NSCLC), due to its crucial role in regulating cell survival and proliferation. Despite the development of first-generation reversible inhibitors like Gefitinib and Erlotinib, acquired resistance necessitated the discovery of highly potent irreversible inhibitors effective against drug-resistant mutants. Molecular docking calculations utilizing both EGFR conformations identified five top-ranked compounds (QN012, QN017, QN019, QN022, and QN023) proposed for synthesis and biological evaluation. These in silico studies predicted high inhibitory activity against the active and inactive state of EGFR. Herein, we report the design, synthesis and biological evaluation of novel 4-anilino quinazoline derivatives, bearing various alkynyl substituents at position 6, expected to bind to the hinge Met793 residue of EGFR. The effects of the derivatives on various cancer cell lines in terms of cytotoxic/cytostatic activity, interference with cell cycle phase distribution, and suppression of EGFR phosphorylation set the basis for the design of more potent derivatives.

  • Rapid detection of soil carbonates by means of NIR spectroscopy, deep learning methods and phase quantification by powder X-ray diffraction

    by Lykourgos Chiniadis, Petros Tamvakis

    In this study we propose a novel rapid and efficient way to predict carbonates content in soil by means of Fourier Transform Near-Infrared (FT-NIR) reflectance spectroscopy and by use of deep learning methods. In addition to using traditional machine learning algorithms, we exploited multiple deep learning methods, such as: 1) a Multi-Layered Perceptron Regressor (MLP) and 2) a Convolutional Neural Network (CNN) in an attempt to compare their performance with other classical machine learning algorithms, which up until now were considered the field’s standards, such as Partial Least Squares Regression (PLSR), Cubist and SupportVectorMachines (SVM) on the combined dataset of two NIR spectral libraries: Kellogg Soil Survey Laboratory (KSSL) of the United States Department of Agriculture (USDA), a dataset of soil samples reflectance spectra collected nationwide, and Land Use and Coverage Area Frame Survey (LUCAS) TopSoil-2015 (European Soil Library) which contains soil sample absorbance spectra from all over the European Union, and use them to predict carbonate content on never-before-seen soil samples. In this study, absorbances in the NIR spectral region (1150-2500 nm) were utilized in two different ways: a) as one-dimensional data and b) as two-dimensional spectrograms which, to our knowledge, is a completely novel approach that has rarely been researched. Quantification of carbonates by means of X-ray-Diffraction is in good agreement with the volumetric method and the MLP prediction. Our work contributes to rapid carbonates content prediction in soil samples in cases where: 1) no volumetric method is available and 2) only NIR spectra absorbance data are available.


  • Open Access

    Discovery of Selective Inhibitor Leads by Targeting an Allosteric Site in Insulin-Regulated Aminopeptidase

    by Ioannis Temponeras, Lykourgos Chiniadis, Athanasios Papakyriakou, Efstratios Stratikos

    Insulin-Regulated aminopeptidase (IRAP) is a zinc-dependent aminopeptidase with several important biological functions and is an emerging pharmaceutical target for cognitive enhancement and immune system regulation. Aiming to discover lead-like IRAP inhibitors with enhanced selectivity versus homologous enzymes, we targeted an allosteric site at the C-terminal domain pocket of IRAP. We compiled a library of 2.5 million commercially available compounds from the ZINC database, and performed molecular docking at the target pocket of IRAP and the corresponding pocket of the homologous endoplasmic reticulum aminopeptidase 1 (ERAP1). Of the top compounds that showed high selectivity, 305 were further analyzed by molecular dynamics simulations and free energy calculations, leading to the selection of 33 compounds for in vitro evaluation. Two orthogonal functional assays were employed: one using a small fluorogenic substrate and one following the degradation of oxytocin, a natural peptidic substrate of IRAP. In vitro evaluation suggested that several of the compounds tested can inhibit IRAP, but the inhibition profile was dependent on substrate size, consistent with the allosteric nature of the targeted site. Overall, our results describe several novel leads as IRAP inhibitors and suggest that the C-terminal domain pocket of IRAP is a promising target for developing highly selective IRAP inhibitors.


  • High-resolution crystal structures of a “half sandwich”-type Ru(II) coordination compound bound to hen egg-white lysozyme and proteinase K

    by Lykourgos Chiniadis, Ioannis Bratsos, Kostas Bethanis, Michael Karpusas, Petros Giastas, Athanasios Papakyriakou

    The high-resolution X-ray crystal structures of the adducts formed between the “half sandwich”-type Ru(II) coordination compound [RuII(1,4,7-trithiacyclononane)(ethane-1,2-diamine)Cl]+ and two proteins, namely hen egg-white lysozyme and proteinase K, are presented. The structures unveil that upon reaction with both enzymes the Ru(II) compound is coordinated by solvent-exposed aspartate residues after releasing the chloride ligand (Asp101 in lysozyme, Asp200 and Asp260 in proteinase K), while retaining the two chelating ligands. The adduct with Asp101 residue at the catalytic cleft of lysozyme is accompanied by residue-specific conformational changes to accommodate the Ru(II) fragment, whereas the complexes bound at the two calcium-binding sites of proteinase K revealed minimal structural perturbation of the enzyme. To the best of our knowledge, proteinase K is used here for the first time as a model system of protein metalation and these are the first X-ray crystal structures of protein adducts of a Ru(II) coordination compound that maintains its coordination sphere almost intact upon binding. Our data demonstrate the role of ligands in stabilizing the protein adducts via hydrophobic/aromatic or hydrogen-bonding interactions, as well as their underlying role in the selection of specific sites on the electrostatic potential surface of the enzymes.


  • Open Access

    The Interaction of the Chemotherapeutic Drug Chlorambucil with Human Glutathione Transferase A1-1: Kinetic and Structural Analysis

    by Michael Karpusas, Irine Axarli, Lykourgos Chiniadis, Athanasios Papakyriakou, Kostas Bethanis, Katholiki Scopelitou, Yannis D. Clonis, Nikolaos E. Labrou

    Glutathione transferases (GSTs) are enzymes that contribute to cellular detoxification by catalysing the nucleophilic attack of glutathione (GSH) on the electrophilic centre of a number of xenobiotic compounds, including several chemotherapeutic drugs. In the present work we investigated the interaction of the chemotherapeutic drug chlorambucil (CBL) with human GSTA1-1 (hGSTA1-1) using kinetic analysis, protein crystallography and molecular dynamics. In the presence of GSH, CBL behaves as an efficient substrate for hGSTA1-1. The rate-limiting step of the catalytic reaction between CBL and GSH is viscosity-dependent and kinetic data suggest that product release is rate-limiting. The crystal structure of the hGSTA1-1/CBL-GSH complex was solved at 2.1 Å resolution by molecular replacement. CBL is bound at the H-site attached to the thiol group of GSH, is partially ordered and exposed to the solvent, making specific interactions with the enzyme. Molecular dynamics simulations based on the crystal structure indicated high mobility of the CBL moiety and stabilization of the C-terminal helix due to the presence of the adduct. In the absence of GSH, CBL is shown to be an alkylating irreversible inhibitor for hGSTA1-1. Inactivation of the enzyme by CBL followed a biphasic pseudo-first-order saturation kinetics with approximately 1 mol of CBL per mol of dimeric enzyme being incorporated. Structural analysis suggested that the modifying residue is Cys112 which is located at the entrance of the H-site. The results are indicative of a structural communication between the subunits on the basis of mutually exclusive modification of Cys112, indicating that the two enzyme active sites are presumably coordinated.